Researchers found that, despite being heavily immunocompromised, haematology patients generate strong cellular immune responses against SARS-CoV-2 after vaccination, on par with that of healthy individuals.
A trial for a nasal spray containing cancer drug interferon developed by scientists at the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital will be expanded into the community.
Updated Jan 26, 2021 | 08:36 IST
The plan to vaccinate the global population against COVID-19 is a noble one, but the importance of treatment to the affected is of prime importance too. Various trials for treatment of COVID-19 | Photo Credit: iStock Images
Key Highlights
Could the common blood pressure medications, called angiotensin receptor blockers, help reduce the impact of coronavirus?
Some scientists in Australia are experimenting on nefamostat, an obscure drug that has been used to treat pancreatitis in Japan and Korea
Could inhaling a common cancer drug and anti-viral called interferon help will stop the COVID-19 virus from infecting people?
Vaccines may not be the silver bullet that will end the COVID-19 pandemic, say, researchers. Since most vaccines aren t 100 per cent effective, it s not likely that they will fortify the entire community. It will be several months before the majority of the population will be vaccinated and till
Tapeworm, vertigo and pancreatitis drugs are being trialled as COVID-19 treatments
By the Specialist Reporting Team s Alison Branley and national medical reporter Sophie Scott
Posted
SunSunday 24
updated
MonMonday 25
Australian researchers are part of global efforts to trial potential COVID-19 treatments.
(
Print text only
Cancel
With COVID-19 vaccines on their way, it s time to breathe a sigh of relief right? Well, maybe not.
Key points:
It includes drugs to treat tapeworm, pancreatitis, vertigo and cancer
Experts warn clinical trials don t always translate into effective human treatments
Most vaccines aren t 100 per cent effective and it s not likely we will achieve full coverage in the community.